Brian Orelli, PhD

At this point, investors are best off with a pick-and-choose strategy.

Revenue growth is slowing as the company has captured a large chunk of its market.

The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment.

Investors will have to wait for the final results from a U.S. based clinical trial.

Short-term investors may not see the long-term potential.

A large portion of the U.S. already has access to the company's services.

There's more to the biotech than its coronavirus vaccine.

The disconnect shouldn't be worrying for long-term investors.

It's been a rough start for the combined generic drug company.

The diagnostic testing company's growth may be slowing, but this shareholder isn't worried.

The biotech's chief medical officer is moving on.

The lower efficacy with an easier dosing regimen puts the healthcare giant in a good position for initial vaccinations, but the vaccine's long-term potential remains in question.

A unanimous committee vote led to the quick authorization.

But 2022 is likely to be the year that defines the company.

The opportunity is bigger than it might at first appear.

The lack of disclosures makes it hard to value the biotech's latest deal.

The booster may not be necessary for short-term coverage, but long-term coverage is still a big unknown.

Short-term issues shouldn't affect long-term investors.

Vaccine makers may have a solution.

The relationship could result in a marriage down the line.